AlloVir and Kalaris Merge to Advance Retinal Therapies
Company Announcements

AlloVir and Kalaris Merge to Advance Retinal Therapies

The latest update is out from AlloVir ( (ALVR) ).

AlloVir, Inc. has announced a merger with Kalaris Therapeutics to form a company focused on retinal diseases, leveraging Kalaris’ TH103 therapy, a novel anti-VEGF treatment. The merger will see Kalaris stockholders own a majority stake, with the combined entity expected to have $100 million in cash, potentially supporting operations into late 2026. The move is set to accelerate the clinical development of TH103, which is currently in Phase 1 trials for neovascular age-related macular degeneration, with results anticipated by Q3 2025.

See more data about ALVR stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyAlloVir to combine with Kalaris Therapeutics in all-stock transaction
TipRanks Auto-Generated NewsdeskAlloVir Finalizes $7 Million Lease Termination Deal
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App